Anixa Biosciences is trading 6.35% up at $3.85, supported primarily by broader biotechnology-sector strength, with XBI up 2.06% during the regular session.
- Its August 24 announcement of an upcoming Cantor Fitzgerald conference highlighted encouraging vaccine and CAR-T clinical progress.
- The release did not report a new approval, financing, earnings result, or trading-related catalyst, and did not mention any share-price reaction.